Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

Advanced BVA System Designed for Faster, Simpler Bedside Testing

Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA.), advancing its mission to optimize healthcare through precise fluid management.

Read more at globenewswire.com